Highest-materiality recent filing
Bausch Health elects Eiry W. Roberts as new director; say-on-pay passes at annual meeting
Eiry W. Roberts elected to board with 196,972,752 votes for, 2,585,679 withheld; broker non-votes 79,859,606.
Bausch Health reports Q1 2026 results; detailed figures not available in excerpt
Filing references earnings press release for quarter ended March 31, 2026, issued April 29, 2026.
Bausch Health changes CEO and EVP PSU settlement from stock to cash for 2023 awards
1,137,862 PSUs for CEO Thomas Appio amended to cash settlement instead of stock upon March 3, 2026 vesting.
Bausch Health reports Q4/FY2025 results; press release content not available in filing excerpt
Quarterly earnings release furnished under Item 2.02; no specific financial data provided in this excerpt.
Bausch Health issues press release on Phase 3 RED-C trial; no details in filing text
Press release announces results of global Phase 3 RED-C program for amorphous-rifaximin in liver cirrhosis.
Bausch Health to reaffirm FY2025 guidance at high end at JPM conference
Presentation at 44th Annual J.P. Morgan Healthcare Conference on Jan 14, 2026 at 3:45 p.m. PT.
Bausch + Lomb closes $2.8B term loan refinancing, reduces margins, extends maturity
Closed $2.802B Replacement Term Loans maturing 2031 to refinance existing term B loans due 2028 and 2031.
Issued $1.6B aggregate principal of new 10.00% Senior Secured Notes due 2032 in exchange for outstanding 4.875% and 11.00% notes due 2028.
Bausch Health completes debt exchange for up to $1.6B in 10.00% senior secured notes due 2032
Exchange offers expired Dec. 23, 2025; old 4.875% and 11.00% senior secured notes due 2028 exchanged for new notes.
Bausch + Lomb refinances $2.8B term loans; margin cut, maturity extended to 2031
$2.802B new Replacement Term Loans to refinance existing term B loans due 2028 and 2031.
Bausch Health announces early results of debt exchange offers; press release details not provided
Company offered to exchange outstanding 4.875% and 11.00% Senior Secured Notes due 2028 for up to $1.6B new 10.00% Senior Secured Notes due 2032.
Bausch Health launches exchange of up to $1.6B notes, offers 10% senior secured notes due 2032
Offers to exchange 4.875% and 11.00% Senior Secured Notes due 2028 for new 10.00% Senior Secured Notes due 2032; up to $1.6B aggregate principal.
Bausch Health announces Q3 2025 results; exhibit with details not provided
Press release for Q3 ended September 30, 2025 issued on October 29, 2025.
Bausch Health shareholders approve Amended and Restated Rights Plan at special meeting
Special meeting held Oct 7, 2025; shareholders voted to ratify the Rights Plan Agreement.
Bausch Health completes acquisition of DURECT for $1.75/share plus CVRs
Tender offer closed with 62% of DURECT shares (19.98M) validly tendered and accepted.
Brett M. Icahn and Steven D. Miller resigned from the board effective August 14, 2025, upon termination of the Director Appointment and Nomination Agreement.
Bausch Health files Q2 2025 earnings release; financial figures not included in provided text
Press release issued July 30, 2025 for quarter ended June 30, 2025.
Bausch Health to acquire DURECT for $1.75/share ($63M upfront) plus up to $350M milestones
Bausch Health will pay $1.75/share cash upfront, valuing DURECT at ~$63M, with up to $350M in additional net sales milestone payments.
Bausch Health appoints Michael Goettler and Sandra Leung to Board, effective July 22, 2025
Board expands from 10 to 12 members with the addition of two new directors.
Bausch Health appoints Steven Lee as SVP, Controller and Chief Accounting Officer
Effective July 14, 2025; Lee will oversee financial reporting and corporate controllership.
Bausch + Lomb closes upsized €675M senior secured notes and $2.325B term loan refinancing
Issued €675M senior secured floating rate notes due 2031 at 3-month EURIBOR+3.875%.
Bausch + Lomb prices €675M secured notes, upsized; new term loan $2.325B
Priced €675M senior secured floating rate notes due 2031 at 99.5% of principal; offering upsized from €600M.
Bausch + Lomb launches €600M senior secured notes offering and $2.2B term loan refinancing
Subsidiaries launch €600M senior secured floating rate notes.
Bausch Health enters standstill-like pacts with Icahn, Paulson, Kavanagh limiting activism
Icahn Group, John Paulson, and Sarah Kavanagh each signed letter agreements with Bausch Health on May 20, 2025.
Bausch Health CAO John Barresi resigns, effective June 2; CFO Charhon to serve as interim CAO
John S. Barresi resigns as SVP, Controller and CAO effective June 2, 2025.
Bausch Health shareholders reelect all 10 directors, approve say-on-pay and ESPP at May 13 AGM
All 10 director nominees elected with over 199 million votes for each; broker non-votes ~56.3M.
Bausch Health Q1 2025 earnings release filed; figures not available in excerpt
Q1 2025 results announced via press release; financial data not included in the provided text.
Bausch Health adopts shareholder rights plan (poison pill) effective April 14, 2025
Board approved shareholder rights plan on April 14, 2025; one right attaches to each common share outstanding.
Bausch Health closes $4.4B 10% secured notes due 2032 and $3B term loan facility
Closed offering of $4.4B aggregate principal of 10.000% senior secured notes due 2032 via subsidiary 1261229 B.C. Ltd.
Bausch Health prices $4.4B 10% senior secured notes due 2032, upsized from $4.0B
Bausch Health priced $4.4B aggregate principal of 10.000% senior secured notes due 2032, upsized from $4.0B.
Bausch Health launches $4.0B secured notes offering and $3.8B credit facilities to refinance debt
Indirect subsidiary launched $4.0B senior secured notes due 2032 to qualified institutional investors.
Bausch Health reports Q4/FY2024 results but filing lacks specific financial figures
Filed an 8-K on Feb 19, 2025, announcing Q4 and full year 2024 results via press release.
Bausch + Lomb borrows $400M in new term loans maturing May 2027
Bausch + Lomb added $400M term loans under its credit agreement; proceeds used to repay revolver and for corporate purposes.
Bausch Health Q3 2024 results announced; no specific figures in filing
Press release attached as Exhibit 99.1 was not included in provided text.
Bausch Health issues Q2 2024 earnings press release; details not available
Form 8-K filed August 1, 2024, referencing press release as Exhibit 99.1.
Bausch Health appoints Jean-Jacques Charhon as CFO, Aimee Lenar as EVP US Pharma
Jean-Jacques Charhon named CFO effective Aug 19, 2024; base salary $700K, target bonus 60%, equity grants ~$3M.
All nine director nominees elected; each received over 170M votes for, with ~70.9M broker non-votes.
Bausch Health releases Q1 2024 earnings; no financial details available
Press release issued on May 2, 2024 for quarter ended March 31, 2024.
until a permanent replacement is in place, at the time that Mr. Barresi ceases to be the Chief Accounting Officer, Jean-Jacques Charhon, who is currently serving as the Company’s Executive Vice President and Chief Financial Officer, will assume the additional role of Chief Accounting Officer.
On May 9, 2025, John S. Barresi informed Bausch Health Companies Inc. (the “Company”) of his decision to resign as the Senior Vice President, Controller and Chief Accounting Officer of the Company.
John S. Barresi, who has served as the Company’s interim Chief Financial Officer since October 2023, will no longer act in this capacity and will continue in his role as Senior Vice President, Controller and Chief Accounting Officer.
On July 15, 2024, the Board of Directors (the “Board”) of Bausch Health Companies Inc. (the “Company”) appointed Jean-Jacques Charhon as the Company’s Executive Vice President and Chief Financial Officer, effective as of August 19, 2024.
Max materiality 0.85 · Median 0.53 · Most common event debt